Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings

Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the study was to compare the baseline characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Philippoteaux, Cécile, Deprez, Valentine, Nottez, Aurore, Cailliau, Emeline, Houvenagel, Eric, Deprez, Xavier, Philippe, Peggy, Pascart, Tristan, Flipo, René-Marc, Goëb, Vincent, Letarouilly, Jean-Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820905/
https://www.ncbi.nlm.nih.gov/pubmed/36615007
http://dx.doi.org/10.3390/jcm12010207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820905/
https://www.ncbi.nlm.nih.gov/pubmed/36615007
http://dx.doi.org/10.3390/jcm12010207

Ejemplares similares